Global InsurTech investment climbed to $5.08 billion in 2025—a 19.5% jump from 2024 and the sector’s first annual funding increase since 2021, according to Gallagher Re’s Q4 Global InsurTech Report. The headline number matters. What sits underneath it matters more.
Why it matters
This is not a return to the 2021 bonanza, when quarterly totals regularly topped $4 billion and valuations floated on growth-at-all-costs assumptions. The 2025 rebound is structurally different in three ways: the capital is coming from different pockets, it is concentrating in a single technology thesis, and the companies receiving it look nothing like the direct-to-consumer disruptors that defined InsurTech’s first wave.
Understanding those shifts is the difference between reading a funding headline and reading the market.
1. The investor base has fundamentally changed
Re/insurers completed 162 private technology investments in InsurTech companies during 2025—more than any prior year on record, according to Gallagher Re. The report describes this as a “changing of the guard,” and the data supports the characterization. Carriers and reinsurers are no longer running innovation labs for optics. They are deploying capital at scale because they view InsurTech infrastructure as central to their own operating strategies.
The implications run both directions. For startups, the path to a check now runs through carrier partnerships as much as Sand Hill Road. For incumbents, the investments signal a strategic bet that it is cheaper to buy innovation than to build it—a calculus that grows more favorable as AI development costs escalate.
Meanwhile, Silicon Valley’s share of InsurTech deal activity is converging with that of reinsurance-backed investors, a trend Carrier Management noted in its Q3 analysis. The traditional VC dominance that defined InsurTech’s early years is giving way to a more balanced—and arguably more sustainable—capital structure.
2. AI is no longer a feature—it is the thesis
Two-thirds of all InsurTech funding in 2025—$3.35 billion across 227 deals—went to companies with an AI focus. In Q4 alone, AI-centered InsurTechs captured 77.9% of quarterly capital at $1.31 billion across 66 deals. The average AI deal size of $22.14 million slightly exceeded the overall Q4 average, suggesting investors are not just chasing a label but backing companies with enough traction to command meaningful rounds.
Andrew Johnston, Gallagher Re’s global head of InsurTech, put it bluntly: the two labels may become synonymous over time, in the same way that “InsurTech” itself is becoming redundant because all insurers are technology businesses.
But concentration at this level carries risk. CB Insights’ latest predictions report warns that a narrowing investor base—the number of investors making four or more InsurTech deals fell to its lowest level since 2017—could shrink the innovation pipeline for incumbents who wait too long to engage. Companies without a clear AI deployment strategy may find themselves choosing from a smaller and more expensive menu of partners.
3. Mega-rounds are back, and they are reshaping the landscape
The number of $100M-plus funding rounds nearly doubled in 2025, rising from six to 11. Five companies—CyberCube, ICEYE, Creditas, Federato, and Nirvana—collectively raised $662.81 million in Q4 mega-rounds alone. These are not consumer brands chasing customer acquisition. They are infrastructure and analytics platforms selling into the carrier value chain.
This pattern reinforces Gallagher Re’s broader observation: InsurTechs have pivoted toward business models that enhance incumbents rather than compete with them directly. B2B tech vendors now represent 58% of P/C deals, a 12-percentage-point increase from the 2021 funding boom. Lead generators, brokers, and MGAs saw their deal share fall to 35%—the lowest on record.
Property and casualty led the recovery with a 34.9% funding increase to $3.49 billion, while life and health declined 4.6% to $1.59 billion. Geographically, U.S.-based InsurTechs captured 55.74% of global deals, up 5.16 percentage points year-over-year—the largest single-country gain.
The question nobody is answering yet
Gallagher Re raises what it calls the “return on investment paradox”: AI is freeing up time and resources inside insurance operations, but the industry has not figured out what to do with that freed capacity. Efficiency gains without a revenue strategy are cost savings at best and headcount reduction at worst—neither of which justifies the valuations investors are assigning to the sector’s most prominent AI companies.
Risk & Insurance’s analysis of the report notes that big tech firms invested more than $1 trillion in AI infrastructure in 2025, and the gap between AI company valuations and their revenue generation continues to widen. InsurTech is not immune to this dynamic. If AI-powered underwriting and claims platforms cannot demonstrate measurable ROI within an 18-month window, the current concentration of capital may start to look less like strategic conviction and more like herd behavior.
What to watch
Three developments will determine whether 2025’s funding rebound marks the start of a durable recovery or a one-year anomaly:
- Re/insurer deal velocity in H1 2026. If carrier-led investments maintain their 2025 pace, the structural shift is real. A pullback would suggest the record year was opportunistic, not strategic.
- AI ROI evidence. Carriers that deployed AI underwriting and claims tools in 2024 should be reporting measurable outcomes by mid-2026. Those results will set the tone for the next funding cycle.
- The IPO pipeline. CB Insights flags growing InsurTech IPO signals. A successful public offering would validate the sector’s maturation narrative and unlock a new exit path that has been effectively closed since 2021.
The InsurTech market is no longer debating whether technology will transform insurance. That question is settled. The live question is who controls the capital that funds that transformation—and in 2025, the answer shifted decisively toward the industry itself.
